Ionis Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Ionis Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- IONS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000874015
Board of directors
-
Allene M. Diaz · DirectorSince 2023
-
B. Lynne Parshall · DirectorSince 2023
-
Brett P. Monia · Director · Chief Executive OfficerSince 2023
-
Joan E. Herman · DirectorSince 2023
-
Joseph H. Wender · DirectorSince 2023
-
Joseph Klein III · DirectorSince 2023
-
Joseph Loscalzo · DirectorSince 2023
-
Ludwig Hantson · DirectorSince 2026
-
Michael J. Yang · DirectorSince 2023
-
Michael R. Hayden · DirectorSince 2023
-
Peter N. Reikes · DirectorSince 2026
-
Spencer R. Berthelsen · DirectorSince 2023
Chief executives
Brett P. Monia
· Chief Executive Officer
Dates unknown
Board connections
7 of this board's directors also sit on 8 other boards.
- via Michael R. Hayden
- via Brett P. Monia
- via Joseph Loscalzo
- via B. Lynne Parshall
- via Joan E. Herman
- via B. Lynne Parshall
- via Joseph H. Wender
- via Michael J. Yang
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,058,700
- 2 purchases by 1 insider
- Sold, last 12 months
- $155,141,362
- 143 sales by 19 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 31, 2026 | BENNETT C FRANK Officer (EVP, Chief Scientific Officer) | Other | +110 | $51.31 | $5,644 |
| Aug 31, 2026 | Birchler Brian Officer (EVP, Corp and Development Ops) | Other | +58 | $51.31 | $2,976 |
| Aug 31, 2026 | Brett P. Monia Director, Officer (Chief Executive Officer) | Other | +98 | $51.31 | $5,028 |
| Aug 31, 2026 | O'NEIL PATRICK R. Officer (EVP CLO & General Counsel) | Other | +63 | $51.31 | $3,232 |
| Jul 31, 2026 | Michael R. Hayden Director | Open-market purchase | +5,000 | $51.60 | $258,000 |
| Jul 30, 2026 | Michael R. Hayden Director | Open-market purchase | +15,000 | $53.38 | $800,700 |
| Jul 15, 2026 | Spencer R. Berthelsen Director | Option exercise | +5,220 | — | — |
| Jul 15, 2026 | Joan E. Herman Director | Option exercise | +5,220 | — | — |
| Jul 7, 2026 | BENNETT C FRANK Officer (EVP, Chief Scientific Officer) | Open-market sale | −5,536 | $83.58 | $462,693 |
| Jul 7, 2026 | Allene M. Diaz Director | Option exercise | +10,111 | $47.11 | $476,329 |
| Jul 7, 2026 | Kordasiewicz Holly B. Officer (EVP, Chief Development Officer) | Open-market sale | −362 | $84.30 | $30,517 |
| Jul 7, 2026 | BENNETT C FRANK Officer (EVP, Chief Scientific Officer) | Other | +15,000 | — | — |
| Jul 7, 2026 | Allene M. Diaz Director | Open-market sale | −10,111 | $85.42 | $863,637 |
| Jul 7, 2026 | BENNETT C FRANK Officer (EVP, Chief Scientific Officer) | Open-market sale | −15,000 | $85.46 | $1,281,930 |
| Jul 1, 2026 | Joseph Klein III Director | Option exercise | +11,518 | $39.94 | $460,029 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.